We use cookies to understand how you use our site and to improve the overall user experience. This includes personalizing content and advertising. Read our Privacy Policy
CTCE 9908 acts as a CXCR4 antagonist that induces mitotic catastrophe in ovarian cancer cells. When given with taxol, it displays additive cytotoxic effects.
CAT No: R0977
CAS No: 1030384-98-5
Synonyms/Alias: CTCE 9908;1030384-98-5;CTCE-9908;UNII-NF0BX95A31;L-Lysinamide, N2,N6-bis(L-lysylglycyl-L-valyl-L-seryl-L-leucyl-L-seryl-L-tyrosyl-L-arginyl)-;NF0BX95A31;PTX-9908 FREE BASE;CTCE 9908 TFA;CTCE9908;SDF-1 Analog PTX-9908;CHEMBL3544949;SDF-1 (108) Lysine Dlmer;CXCR4 Antagonist CTCE-9908;PTX9908;PTX 9908;PTX-9908;SDF-1 Receptor Antagonist PTX-9908;DA-52152;G14352;Q27284835;L-Lysinamide,N2,N6-bis(L-lysylglycyl-L-valyl-L-seryl-L-leucyl-L-seryl-L-tyrosyl-L-arginyl)-;
Quick InquiryCustom Peptide SynthesisPeptide Library Construction and Screening
Powerful screening tools in biological and chemical research
M.F/Formula | C86H147N27O23 |
M.W/Mr. | 1927.3 |
Sequence | Three Letter Code:H-Lys-Gly-Val-Ser-Leu-Ser-Tyr-Arg-Lys(1)-NH2.H-Lys-Gly-Val-Ser-Leu-Ser-Tyr-Arg-(1) |
Labeling Target | CXCR4 |
Appearance | White lyophilised solid |
Purity | >98% |
Activity | Antagonist |
Long-term Storage Conditions | Soluble in water |
InChI | InChI=1S/C86H147N27O23/c1-45(2)35-58(104-81(133)64(43-116)110-83(135)68(47(5)6)112-66(120)39-99-71(123)53(89)17-9-12-30-87)75(127)108-62(41-114)79(131)106-60(37-49-22-26-51(118)27-23-49)77(129)102-56(20-15-33-97-85(92)93)73(125)96-32-14-11-19-55(70(91)122)101-74(126)57(21-16-34-98-86(94)95)103-78(130)61(38-50-24-28-52(119)29-25-50)107-80(132)63(42-115)109-76(128)59(36-46(3)4)105-82(134)65(44-117)111-84(136)69(48(7)8)113-67(121)40-100-72(124)54(90)18-10-13-31-88/h22-29,45-48,53-65,68-69,114-119H,9-21,30-44,87-90H2,1-8H3,(H2,91,122)(H,96,125)(H,99,123)(H,100,124)(H,101,126)(H,102,129)(H,103,130)(H,104,133)(H,105,134)(H,106,131)(H,107,132)(H,108,127)(H,109,128)(H,110,135)(H,111,136)(H,112,120)(H,113,121)(H4,92,93,97)(H4,94,95,98)/t53-,54-,55-,56-,57-,58-,59-,60-,61-,62-,63-,64-,65-,68-,69-/m0/s1 |
InChI Key | VUYRSKROGTWHDC-HZGLMRDYSA-N |
Isomeric SMILES | CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCCCC[C@@H](C(=O)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCCCN)N)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCCCN)N |
3. Myotropic activity of allatostatins in tenebrionid beetles
5. Immune-awakening Saccharomyces-inspired nanocarrier for oral target delivery to lymph and tumors
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at info@creative-peptides.com. We will endeavor to provide highly satisfying products and services.
USA
Address: SUITE 115, 17 Ramsey Road, Shirley, NY 11967, USA
Tel: 1-631-624-4882
Fax: 1-631-614-7828
Email: info@creative-peptides.com
Germany
Address: Industriepark Höchst, Gebäude G830
65929 Frankfurt am Main
Email: info@creative-peptides.com